Speedel board recommends acceptance of Novartis offer
This article was originally published in Scrip
Executive Summary
Speedel's board of directors has recommended that its shareholders accept the offer made by Novartisto acquire the company for CHF130 ($126) per share. Novartis bought 51.7% of the shares in Speedel in July, bringing the total amount of shares it owned to 61.4%, and subsequently began a mandatory tender offer to acquire the company. The offer, which was in the mid-third of analyst recommendations, is considerably higher than the average price of Speedel's shares for the 60 trading days before the announcement of the offer – CHF72.19 – and Novartis expects the full acquisition to cost CHF907 million (Scrip Online, July 10th, 2008).
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.